• CubCrafters owns 15 undeveloped acres at McAllister Field for potential expansion of operations
• The company recently opened a new 11,000-square-foot Customer Completion Center
• Cost and timeline of FAA Certification represents a significant barrier to entry
• The company introduced its CC19-180 XCub aircraft in June 2016, completing the six-year project without using any outside investment
• The company recently released new variants of the XCub offering floats and more engine horsepower
• New nosewheel configurations open up the company’s product line to 85% of all pilots
• Only 10-12% of CubCrafter’s sales are international, though it represents 50% of the market demand – an untapped opportunity for growth
• Financing will dramatically reduce order backlog resulting in a strong revenue rise and accelerating future growth
• The Builder Assist program, unique to CubCrafters, is a large and growing sales segment
• The company’s legacy of innovation distinguishes it from its peer group
• The global ultralight and light aircraft market was valued at $7.63 billion in 2021 and is expected to grow at a CAGR of 4.5% from 2022 to 2027 to reach a forecast value of $9.93 billion

Cub Crafters (typically styled CubCrafters) is an OEM aircraft manufacturer based at McAllister Field Airport in Yakima, Washington. The company was founded in 1980 to build parts and supplementary type certificate (“STC”) improvement modifications, which were used to establish it as the preeminent center for rebuilding the classic Piper PA-18 Super Cub light aircraft. CubCrafters went on to advance the market with its own, newly manufactured aircraft models and holds an approved Federal Aviation Administration (“FAA”) Production Certificate. Yakima-based operations include an engineering design-test-certification center, aircraft parts and assembly production facilities, and an MRO maintenance service and overhaul facility. The first newly manufactured aircraft by the company, the CC18-180 Top Cub, was Federal Aviation Administration (“FAA”) type certified in December 2004. The Top Cub was also granted type certificates (“TC”) by Transport Canada in July 2008, followed by Australian certification in August of that same year. With the FAA’s release of the new Light Sport Aircraft (“LSA”) class, CubCrafters created a brand-new model in 2008, the CC11-100 Sport Cub, similarly based on the original Piper J-3 Cub’s appearance, which it validated to ASTM international standards as an LSA. This model advanced to become known as the Carbon Cub, the bestselling LSA of all time in the U.S. CubCrafters focuses on four main product lines, including the Carbon Cub SS, Carbon Cub FX, XCub, and the Top Cub under license. Some models are built to be lightweight and powerful for quicker flights, while others are built for longer missions in unforgiving backcountry environments. CubCrafters has a service and overhaul facility for PA-18 Super Cubs and other Cub derivative designs at its Yakima headquarters. The company sells aircraft kits as well as finished aircraft. Aircraft The Carbon Cub is available in three variants: Carbon Cub SS (production Light Sport Aircraft), Carbon Cub FX (an innovative Builder Assist E/A-B aircraft) and Carbon Cub EX (E/A-B aircraft kit). Carbon Cub has been designed for off-airport operation with a powerful engine, strong lightweight airframe and nimble low-speed manners. The Carbon Cub has taken the fundamentally superior design of the Piper Super Cub and reinvented it using 21st century materials and computer-aided design. Superior engineering results include the Carbon Cub having 50% fewer parts and weighing more than 300 pounds less than a similarly equipped Super Cub. Now in its third generation of innovation advancements, there are over 1,000 Carbon Cubs flying. The CubCrafters CC19-180 XCub, FAA Certified and introduced in June 2016, is supplied complete and ready-to-fly. The XCub is a further scaled development of the CubCrafters Carbon Cub, which the company continues to supply, but with higher performance and incorporating more structural carbon fiber. The XCub was developed over a six-year period and not publicly announced until FAA TC had been completed and issued. The process was completed organically using company resources and did not involve any venture capital, loans nor any advanced customer deposits. XCub is built on a wholly original fuselage design. The CNC-milled 4130 chromoly steel frame meets the latest FAA Part 23 certification standards for 2,300-pound gross weight aircraft. XCub’s useful load is as high as 1,084 pounds. Current Part 23 certification requirements ensure this is the strongest Cub ever produced. It can fly farther, providing greater comfort. It is an airplane that has taken the best from the past and, using the very latest in design, material and manufacturing technology, has established a new standard. The XCub was approved by the FAA for seaplane operations in December 2017. That same month, EASA approved the XCub design and issued a new type certificate. Four international type certificates have been gained: EASA Dec-2017, Canada Feb-2018, Japan April-2018, and Australia Aug-2018. CubCrafters increased the horsepower of the XCub line in 2019, offering two new models: the CC19-215 FAA Certified version and the CCX-2300 Builder Assist, both powered by the new CC393i 215 HP engine built by Lycoming. In December 2021, CubCrafters gained FAA Certification of a new nose wheel version of the XCub, branded the NXCub. Market Overview According to a 2022 analysis by research firm Expert Market Research (“EMR”), the global ultralight and light aircraft market was valued at $7.63 billion in 2021. The EMR report says the market is expected to grow at a CAGR of 4.5% in the forecast period of 2022-2027 to reach a value of $9.93 billion. Ultralight and light aircraft are small aircraft with on-board pilot (and perhaps passengers) designed for use in recreation, sports, pilot training, aerial surveys, mapping, research and agriculture, humanitarian backcountry access, and special military missions, as well as business and personal travel. CubCrafters currently enjoys a dominant market share of the rugged adventure airplane market. Management Team Patrick Horgan is President and CEO at CubCrafters. Before he assumed that role, he was the company’s Vice President/Director of Engineering & Product Development for three years, when he led the FAA Part 23 type certificate approval and production certificate approval of CubCrafters’ newest flagship, the XCub. Mr. Horgan also directed the breakthrough certification that authorized the use of experimental avionics in FAA-certified production aircraft, a first in aviation history. He brings over 30 years’ aircraft development and manufacturing experience in general aviation, commercial, and military industries. Prior to service at the company, he was the General Manager at WACO Classic Aircraft Corporation in Battle Creek, Michigan, and was the commercial aircraft manager of the Boeing 777 wheel and brake program for Goodrich Aerospace in Troy, Ohio. He was also a designer on the F/A-18 Super Hornet at McDonnell Douglas (now Boeing) in St. Louis, Missouri. Mr. Horgan holds degrees in aeronautical and astronautical engineering from the University of Illinois, and a certificate in Disruptive Strategy from Harvard Business School. He serves as a member of the Board of Directors of the General Aviation Manufacturers Association and on ASTM aircraft standards committees. Brad Damm is Vice President at CubCrafters. He has overseen CubCrafters’ sales, marketing, and brand management operations since 2018. Since first joining CubCrafters in 2013, Mr. Damm has served as Factory Direct Sales Manager, the Director of Sales Support, the Global Director of Sales, and the Vice President of Sales and Marketing. During his tenure, the company has seen new sales records year after year across all of CubCrafters new aircraft and kit product lines, and the CubCrafters brand has risen to new levels of awareness and respect with aviation consumers worldwide. Prior to joining the company, he served for over 10 years as the Business Development Manager for one of the largest commercial concrete contractors in the Pacific Northwest, driving the sales and revenue growth that allowed the company to expand from a few dozen to hundreds of employees. Rick Johnson is the Director of Finance at CubCrafters and has been with the company since 2017. He has 27 years of previous experience as controller and CFO for fruit packing and timber operations in the Pacific Northwest. He holds a Bachelor of Science in Business Administration from Central Washington University. Christopher Matus is Production Manager at CubCrafters and joined the company in 2011. Before taking that post, he held positions as Fabrication Plant Manager, Machine Shop Manager and CNC Machinist for the company. He has also served as a Combat Engineer in the Washington Army National Guard, deploying to Afghanistan and to natural disasters including the 2014 Oso Mudslide. Justin Jansky is the Administrative Manager at CubCrafters. He joined the company in 2015 and has a demonstrated history of successful collaboration on major FAA type certification projects in the general aviation industry, specifically under 14 CFR Parts 21 and 23. He is responsible for process management, document control, facilitating FAA certification processes, coordination with FAA delegates and documenting compliance testing. He holds a bachelor’s degree in technology and applied design. For more information, visit the company’s website at www.CubCrafters.com. NOTE TO INVESTORS: The latest news and updates relating to Cub Crafters Inc. are available in the company’s newsroom at https://ibn.fm/CUB

• Lexaria, a global innovator in drug delivery technology, has developed the patented DehydraTECH(TM) technology which has been the subject of several issued patents
• Recently, Lexaria reported it had been notified of the allowance of its 26th worldwide patent with a new patent to be granted in Japan
• The patent is the fourth to be granted in Japan and the first patent issued from Lexaria’s seventh patent family
• Lexaria also submitted a briefing book to the FDA to facilitate its upcoming pre-Investigational New Drug (“IND”) meeting with the agency

“We are extremely pleased to have received our first patent protecting our proprietary technology… I expect our intellectual property portfolio to continue to expand,” said Lexaria Bioscience (NASDAQ: LEXX) CEO Chris Bunka in an October 2016 press release announcing that the company had been issued U.S. Patent No. 9,474,725, Cannabinoid Infused Food and Beverage Compositions and Methods of Use Thereof, by the U.S. Patent and Trademark Office (“USPTO”) (https://ibn.fm/iW3Ai). Since receiving this patent, its first ever, which pertains to LEXX’s method of enhancing bioavailability and taste of specific cannabinoid lipophilic active agents in food products, the company has amassed an impressive portfolio worldwide that includes patents granted in India, Australia, Japan, the U.S., Mexico, and Europe, and is, in fact, still growing as its patent applications advance to granted patents. Lexaria is pursuing patent protection in over 40 countries and currently has roughly 50 pending patent applications globally (https://ibn.fm/R3jaO). In a development that now pushes the number of granted patents worldwide to 26, Lexaria recently reported it had been notified of the allowance of a new patent to be granted in Japan, the fourth to be granted in that country. Entitled Lipophilic Active Agent Infused Compositions with Reduced Food Effect, this is the first patent issued from Lexaria’s seventh patent family and refers to tetrahydrocannabinol (“THC”) (https://ibn.fm/Hr8E2). The new patent acknowledges DehydraTECH(TM)’s ability to deliver active pharmaceutical ingredients (“APIs”) more efficiently, in a process known as absorption, regardless of the presence of food in the gastrointestinal system. Ordinarily, food impacts drug absorption by physically interacting with drugs, altering the pH, stimulating bile flow, slowing gastric emptying time, or increasing splanchnic blood flow (https://ibn.fm/Udtkw). But DehydraTECH, Lexaria’s patented drug delivery technology, delivers drugs more consistently into the bloodstream regardless of this food effect. The drug delivery technology achieves this through its use of fatty acid oil. Lexaria’s technology joins the API’s molecules in what is believed to be a “barbell-shaped” structure that allows the body to detect both molecules while enhancing taste and absorption. The body’s detection and natural processing of the long chain fatty acid is part of Lexaria’s clever patented process that also enhances the API absorption. Bioavailability refers to both absorption levels and the time required to absorb. “In order to feel something quickly, you need to avoid something that’s known as fast-pass liver metabolism. When you eat food, it goes into your stomach, then it goes into your intestine, and then most of the nutrients go into your liver for filtration before they get into the bloodstream. That takes about an hour and a half, on average. But [using] our technology, we are able to divert the molecules away from the liver, and that allows you to get feelings or experiences in as little as 15 to 20 minutes,” Chris Bunka continued. Meanwhile, Lexaria also reported it had submitted its briefing book to the U.S. Food and Drug Administration (“FDA”). This documentation will facilitate a pre-Investigational New Drug (“IND”) meeting that LEXX had requested in an early June letter to the FDA. The FDA provided a target date of July 30, 2022, for a meeting or comments. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Silo Pharma produced initial batch of SPU-21 liposomes for rheumatoid arthritis study conducted by CRO Frontage Laboratories
• Recent company research revealed SPU-21 liposomes can target inflamed epithelium, suggesting use for targeted drug delivery
• SPU-21 can be used for development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis
• Company recently announced positive results in subcutaneous delivery of novel liposomes vs. intravenous injection

Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company that focuses on fusing traditional therapeutics with psychedelic research, recently announced it had produced an initial batch of SPU-21 liposomes for a rheumatoid arthritis study conducted by Frontage Laboratories, a contract research organization (“CRO”) (https://ibn.fm/BizI3). Recent research by the company revealed that SPU-21 liposomes have the ability to target inflamed epithelium, suggesting they can be used to target drug delivery. Further, SPU-21 can potentially be used to develop fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. According to the research, this approach may enhance therapeutic effects and decrease potential toxicity despite systemic administration of the drug. “The production and delivery of liposomes for our upcoming study with Frontage advances SPU-21 and allows us to further study anti-arthritic activity in animals,” said Eric Weisblum, CEO of Silo Pharma. “We look forward to sharing the results of the study upon completion and data collection.” In addition, Silo recently announced positive results in subcutaneous delivery of its novel liposomes to treat arthritic patients (https://ibn.fm/XeEiQ). This contrasts with previous animal research testing ART-1-Cy7 liposomes using intravenous injection, suggesting that subcutaneous administration possibly trends higher than intravenous injection with fewer toxic effects. “The successful results of our study show that the subcutaneous route of liposomal administration is well-suited for use in targeted drug delivery of anti-arthritic agents,” said Weisblum. “We suggest that this drug delivery approach would not only enhance efficacy but also reduce systemic toxicity.” ​Silo partners with leading universities to further treatment research for various mental and physical indications. The company recently extended its exclusive option agreement with the University of Maryland, Baltimore, to explore joint-homing peptides to treat arthritis in addition to Multiple Sclerosis (“MS”). In addition, the company signed an agreement with Columbia University that granted an option to license developmental assets that include an Alzheimer’s disease formulation as well as a prophylactic treatment for post-traumatic stress disorder (“PTSD”). Silo is dedicated to leveraging innovative solutions to help people suffering from indications such as rheumatoid arthritis, fibromyalgia, post-traumatic stress disorder (“PTSD”), Parkinson’s disease, Alzheimer’s disease, and other rare neurological disorders. The company identifies and partners with leading medical universities, providing financial resources that catalyze the progress of cutting-edge research through the clinical stage and into commercialization. For more information, visit the company’s website at www.SiloPharma.com. NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

• Nearly a decade has passed since approximately 200 government entities met in Paris, ratifying a binding agreement to work toward reducing pollution and its negative impacts on global climate
• Louisiana-based Correlate Infrastructure Partners is helping to educate corporate clients on both the affordability and potential profit offered by ESG solutions that reduce their greenhouse gas impact
• CIPI’s Correlate, Inc. and Loyal Enterprises LLC (dba Solar Site Design) subsidiaries provide related help on acquisitions and project development, as well as resource financing
• A recent report by consulting firm McKinsey & Company forecasts growing adoption of renewable energy solutions by the public, but at a pace that will, at the current rate, fall short of the established Paris goals

Purpose-built energy use optimization company Correlate Infrastructure Partners (OTCQB: CIPI) works with business clients to improve their facilities’ consumption of utilities and production of greenhouse gases. Environmental, social and governance (“ESG”) initiatives have become increasingly important amid concerns about climate change and its expected negative effects on society. In April, Renewables e-magazine noted that green energy solutions are increasingly forming the basis for utilities related decisions, and that global management consulting firm McKinsey & Company’s latest report on the energy sector predicts that by the end of the decade approximately 50 percent of power resources will be based upon renewables, and that this percentage will rise to 85 percent by 2050. The costs of implementing solar or onshore wind power have previously made such solutions inaccessible to some companies and utilities. However, as their expense has fallen, they have become more attractive. “Rapid technological developments and supply chain optimization have collectively halved the cost of solar, while wind costs have also fallen by almost one-third,” McKinsey senior partner Christer Tryggestad stated in conjunction with the report (https://ibn.fm/JQ5lw). “However, even if all countries with net zero commitments deliver on their aspirations, global warming is still expected to reach 1.7°C. To keep the 1.5°C [Paris Agreement] pathway in sight, even more ambitious acceleration is needed.” The 2015 Paris Accords have had nearly a decade to work on the public consciousness of concerns about changing weather patterns which scientists verify are prompted by manmade pollutants. Political factions, resistant to changes and decisions that might include higher costs in order to reduce pollution, have slowed the pace of new policy adoption, but activists continue to see optimism in the trends toward large-scale acceptance. Still, the McKinsey report’s statement that the countries involved in the agreement are only on pace to achieve a 1.7 degree increase over pre-industrial levels by mid-century indicates that the global climate is still going to experience upheaval if a larger response doesn’t occur. Correlate Infrastructure Partners provides education to companies and organizations on both the affordability and potential profit of their environmentally friendly solutions. Through CIPI’s advisory assistance on acquisitions and project development, paired with development and financing resources, the company is helping to turn ESG strategies into a financially viable reality. Clients simply need to provide CIPI with 12 months of utility bills and opt-in to CIPI’s advisement. Determined solutions may involve improvements to HVAC, mechanical, electrical and plumbing processes, the addition of solar upgrades, water optimization and antimicrobial airflow, the strategic procurement of energy sources, vehicle electrification, and master controls that provide intelligent oversight of any retrofits. The reporting process provides a thorough and transparent analysis of what is achieved through these solutions, and how they can represent not only affordability but potential profit for the companies and organizations being served. For more information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• Hillcrest announces AGM results; all seven members of Board of Directors are re-elected while new board chair David Farrell is appointed
• Company exits fossil-fuel business and completes transition to clean tech market where it continues to develop inverter technology empowering next generation of more efficient and powerful electric vehicles
• Hillcrest reaches key milestone as it completes proof of concept testing of its inverter technology, with the commercial prototype soon to be available in Q4 2022

Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA), a Canadian cleantech company developing technologies for innovative electrical solutions such as powertrains and grid-connected renewable energy systems, has announced the voting results from its Annual General Meeting held Wednesday, June 29, 2022. The Board of Directors and Management received extraordinary support from shareholders, who overwhelmingly voted in favor of the proposed items, including the composition of the Company’s leadership. Hillcrest also announced the completion of its transition toward clean energy technologies by formally announcing the end of its oilfield activities (https://ibn.fm/pRIUD). All seven of Hillcrest’s Board members have been re-elected, with a new Chair, David Farrell, heading the team as the previous Executive Chair, Michael Krzus, stepped down after having served for the past seven years. Mr. Farrell, who has also served on the Hillcrest Board for the past year, brings to the team more than 25 years of corporate and investment banking experience, working with a number of global junior and mid-tier companies through their major growth stages. As part of its commitment to environmentally responsible operations, Hillcrest recently decided to change the Company’s direction towards the exit from the fossil fuel business and focus its efforts on commercializing clean technologies. The Company is confident that Mr. Farrell is well-positioned to lead Hillcrest as it evolves into a mature, clean energy technology company. With ambitious plans for its clean tech future, Hillcrest also solidified its technical team with Ronald Rebeiro, an electrical machine design and motor drives expert who holds a Ph.D. in electrical and electronics engineering. Mr. Rebeiro is expected to focus on engineering project management and testing activities at the Company’s Vancouver tech development lab (https://ibn.fm/4twvs). Hillcrest continues to make strides in its new clean tech market, where it concentrates on offering a flexible, single-inverter architecture applicable at nearly every stage of the electrification ecosystem, from renewable energy generation through the charging and operation of electric vehicles to providing full-cycle efficiency and performance improvements. The Company has completed proof of concept testing of its EV traction inverter, demonstrating a reduction in switching losses of +90% compared to conventional, hard-switched inverters employed in many electrical vehicles today. Work is currently underway on the commercial prototype for its EV traction inverter, expected to be available to customers in Q4 2022. The new test signifies a key milestone in the commercialization testing protocol as it examined specifically the efficiencies enabled by Hillcrest’s soft-switching technology. Due to the trade-off between the optimal switching behavior and acceptable thermal losses, currently deployed electric motors operate within a switching frequency range of 8kHz to 16kHz. Hillcrest’s high-efficiency inverter could be a game changer for next generation EVs as it is able to soft-switch at much higher frequencies without causing additional losses. As a result, the new technology could potentially enable motor manufacturers to take advantage of new motor concepts beyond the scope currently available. These potential efficiencies, previously unimaginable, could allow higher power density, lower cost and weight and better power quality and EV performance in the future. More details are available in the recent technical whitepaper published on the Hillcrest website at www.HillcrestEnergy.tech. NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF

• Data from newly acquired study could accelerate clinical development of CYBN’s CYB004 by nine months
• The pivotal study was designed with four primary objectives
• Cybin’s proprietary substance has potential to effectively treat anxiety disorders, including GAD and SAD

Cybin (NEO: CYBN) (NYSE American: CYBN) has completed the acquisition of the largest dimethyltryptamine (“DMT”) study to date, a Phase 1 N,N-DMT study that provides key data relating to the company’s proprietary CYB004 substance (https://ibn.fm/2Ab0T). Information from the study is expected to help the company accelerate by up to nine months its clinical development pathway of CYB004. “With the closing of this transaction we are well on our way to advancing CYB004 through Phase 1 development and gathering essential safety and dosing optimization data that will inform the clinical path forward for this important molecule,” said Cybin CO Doug Drysdale. “Cybin now has multiple clinical-stage programs ongoing that we believe will contribute significantly to a greater understanding of the potential of psychedelics to provide therapeutic relief to patients who suffer with a variety of mental health issues.” The Phase 1 EBRX-101 study, now named CYB004-E, was acquired from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) through Cybin IRL Limited, Cybin’s wholly owned subsidiary. The study was designed with four primary objectives: to evaluate the safety of increasing doses of a single-dose, continuous DMT infusion over 90 minutes; to characterize the PK of a single-dose DMT administered continuously over 90 minutes; to characterize the PD of a single-dose DMT administered continuously over 90 minutes; and to establish the minimum DMT dose required to produce a psychedelic effect. The adaptive, randomized, double-blind, placebo-controlled, single-ascending-dose study produced notable results. According to the study, inhaled CYB004 showed an estimated 2,000% improved bioavailability compared with orally administered DMT and a 41% improved bioavailability compared with inhaled DMT. In addition, Cybin’s CYB004 demonstrated an approximately 300% longer duration of effect when compared with IV DMT as well as a rapid onset of effect and low variability equivalent to IV DMT. Cybin plans to evaluate the results from this study, along with other key data, to identify the next steps forward for its proprietary substance. “The most precious commodity in drug development is time, and acquiring this robust Phase 1 study already underway potentially accelerates the CYB004 development program by approximately nine months,” said Drysdale. “The PK findings from the CYB004-E study should also help to inform the clinical path forward for this innovative and proprietary molecule. This transaction also provides Cybin with access to a world-class research foundation and the privilege to work with the Entheon team, who offer a wealth of knowledge and expertise in this psychedelic class.” CYB004 is a new chemical entity for which a patent was issued by the U.S. Patent and Trademark Office in February 2022. The proprietary substance has the potential to effectively treat anxiety disorders, including generalized anxiety disorder (“GAD”) and social anxiety disorder (“SAD”). In its natural form, DMT is rapidly metabolized in the body and is not orally bioavailable. However, preclinical studies, including the CYB004-E study, have demonstrated that CYB004 has the potential to overcome these issues and provide increased oral and pulmonary bioavailability, faster onset with lower doses, low interpatient variability, and better dose titration, with fewer side effects and longer-acting desensitization of the serotonergic receptors. Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• GMGI CEO says new P2P Esports offering coming “quite soon”
• Gaming operators have need for new products to grow market share
• New product overcomes challenges related to compliance in Esports gambling

If you’re paying attention to the sports betting market, you’re seeing companies big and small looking for edges to capture market share from competition in a fierce, albeit huge, marketplace. It’s tough to carve out profits when, in the words of Brian Goodman, CEO of Golden Matrix Group (NASDAQ: GMGI), “everyone [is] fishing in the same pond.” Companies must be differentiated, as is Golden Matrix, a provider of turnkey and white label gaming platforms, Esports technology, and gaming content that has notched 15 straight profitable quarters. As more and more U.S. states legalize online gambling, there is room for vertical growth for sportsbooks, daily fantasy sports (“DFS”), and casinos. However, operators need to continue to follow trends to get into the pockets of new players. Many of these players win and retention opportunities are centered on non-professional betters, women, and younger players that don’t seem to want to follow conventional betting modalities. That is leading to a race to establish a footprint in Esports gambling and peer-to-peer betting, amongst other things. These are some of the immediate blue-sky chances to juice revenue streams or get fledgling companies off the ground. Golden Matrix’s roots are in B2B (business-to-business) gambling, where its technology is used by over 500 casino operators serving 7+ million players. The Las Vegas-based company has recently branched out into B2C (business-to-consumer) offerings through the acquisition of 80% of UK-based skilled competition operator RKingsCompetitions Ltd. Golden Matrix was recently featured in financial media and data company Benzinga’s Esports Listmakers Series where Goodman spoke about the state of the industry and some of the challenges involved with Esports and betting on them. It’s not as simple as being a facilitator of two friends betting who has more kills in any specific Esports game. For one thing, gambling on smaller events in sports known for rapid player turnover mean greater opportunities for collusion. Plus, operators are responsible for ensuring all government regulations are followed regarding money transfer, bettor locations, and, amongst other things, the age of gamblers. In jurisdictions around the world, bettors must be a minimum of 18 years old, and 21 in many cases (or even 25, as in Portugal). This is critical with respect to Esports, where players and fans tend to be from younger demographics. The average competitor in Blizzard Entertainment’s Overwatch League is about 20 years old. Players aren’t much older in Activision’s Call of Duty League (average age is 22 years). In the Overwatch League, the average retirement age is just 23. Goodman says his company will be releasing a new peer-to-peer Esports betting platform “quite soon.” There have been some delays in launching the product even though it is in a Beta testing stage as we are waiting for our Mexican facing casino to be launched which should happen in the coming weeks. The Esports product allays concerns about following regulatory guidelines in the burgeoning market and is seen as a good fit for its existing user base and way to generate additional revenues in Mexico and in Asia-Pacific, Golden Matrix’s biggest market currently. For more information, visit the company’s website at www.GoldenMatrix.com. NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

The EV Charging Conference 2022 is a 2-day virtual event designed to optimize education, learning, and networking among industry professionals in the electric vehicle market and other participants. The highly specialized event focuses on addressing fundamentals at residential and commercial levels to drive ROI across the EV landscape and clean energy. Key Details

• The push for NetZero is creating a massive, untapped opportunity for EV Charging
• Reinvent your electric strategy for residential or commercial properties
• Thought leaders will share their knowledge, skills, and expertise to enable the successful integration of profitable EV charging into your organization

The forthcoming EV Charging Conference will be held in a completely virtual format on August 11-12, 2022, by the Global Strategic Management Institute (“GSMI”), a cutting-edge conference production firm focused on fostering disruptive innovation. This conference provides a world-class platform geared towards untapped knowledge sharing, networking with industry speakers, learning about emerging technologies and fresh incentive structures, fostering innovative, collaborative relationships, and adopting successful strategies to enable your organization to be at the frontline of innovation and drive profit margins.  Core attendees will include C-suite executives, senior leadership, and middle management from Operations, Business Development, and Fleet Operations in various allied sectors and verticals, including alternative fuels, energy technology, city and urban planning, OEMs, EV strategy, and municipalities to name a few. Why Should You Attend? The conference aims to offer deep insight to the EV and clean energy communities about the most relevant investment and development strategies in installation, technology, and the broader industry across residential and commercial opportunities. Participants will gain a perspective into the EV charging landscape that can be tailored to their business models. Participants will experience real-time presentations in the sessions rooms, where they can enter and exit at their convenience, chat with other participants and interact directly with speakers. The conference also supports Real-Time Networking, enabling attendees, speakers, and sponsors to engage through dedicated chat functions and build lasting relationships during designated networking breaks, at topic-specific tables and in group discussions. Participants can also schedule one-on-one 15-minute video meetings with any of the 500+ EV charging professionals in attendance, all via a single seamless virtual forum. The two-day conference will host a comprehensive roster of senior-level executive leaders offering a rich, diverse mix of perspectives and knowledge. Attendees will have access to interactive and comprehensive panel discussions on wide-ranging topics, including The Demand for Investors (Artificial Intelligence, ROI, Planning); EV Reliability, Maintenance, and Cellular Communications; Collaborating with Municipalities and States; Funding Site Improvements: Getting the Most out of Incentives and Grants; Leveraging Available Technologies: Values of Charging Management, Bidirectional Charging and More; Prioritizing EV Charging at the Commercial Level; How HOA and Multi-Dwelling Complex Owners Navigate EV Charging Stations; and Fleet Electrification. Keynote Panels will also be held on Day 1 and Day 2, on The Future of EV Charging with Ahmed Mousa, Lead Utility of the Future at PSEG, and Andrew Duvall, Transportation Behaviour Analyst, NREL, as well as The Challenges of EV Charging with Fabio Mantovani, VP of eMobility at NY Power Authority; Adriana Perez, Enterprise Growth Acceleration at WOOD PLC; and John Erdman, Head of Strategic Accounts at FreeWire Technologies, respectively. The event will provide participants access to solo presentations from industry veterans on topics such as “Start to Finish: Site Evaluation and Installation for Sustainable EV Charging”, and “Power Storage and Management of Buildings and Batteries.” The EV Charging Conference is a marquee, must-attend event that will officially launch an exciting EV Charging event series. The lead event this August will focus on the opportunities and challenges faced by residential and commercial decision-makers. This will be followed by the second event of the series on October 18-19, 2022, with the EV Charging Infrastructure Conference, also in an easy-to-access fully virtual mode. Discussants will concentrate on the scaling-up of infrastructure to meet future demand for EV charging facilities, and will play host to city and urban planners, officials from leading utilities, government organizations, and electrical contractors. In February 2023, the series will move to its third and final event, a fascinating in-person expo, showcasing the latest developments across six key tracks including charging infrastructure; hardware, and software technologies; connecting consumers; business strategies; funding, and investments; and OEM manufacturing. To register for the conference, click here. For information on group discounts, contact Jessica Vargas or call 619-597-7315. To speak at the conference, become a sponsor, or for general inquiries, click here.

• Medical technology innovator Odyssey Health Inc. is using clinical tests to establish the safety of a therapy designed to treat concussion injuries in its earliest moments
• The company is enthused by results from the early-stage testing and is preparing to design a Phase II/III trial that will target efficacy results in volunteer subjects, focusing particularly on members of the military
• Odyssey’s technology combines a synthetic medication with a specially designed application device that helps the medication cross the blood-brain barrier for immediate responsiveness following a mild traumatic brain injury (“mTBI”)
• Medication for concussion treatment remains an unmet need and Odyssey is aiming to be a first-mover in the healthcare sector

The National Council on Aging sponsors its Falls Prevention Week timed, not ironically, during the fall of each year, using its national health campaign to combat the leading cause of fatal and non-fatal injuries among older adults. One message of the council’s awareness campaign is the importance of recognizing that after an old person is helped back up, the fall victim may be able to resume walking, but there is still a significant risk of worsening effects from a concussion-related head injury (https://ibn.fm/rRsst). While the potential harm of concussion injuries in youth sports and among professional athletes is gaining an increasing measure of attention, concussions in elderly fall patients is also a prominent concern, and active military personnel also continue evaluating potential new treatments for concussion injuries sustained on duty. Medical device innovator and biopharmaceutical product developer Odyssey Health (OTC: ODYY) is working to address unmet needs in concussion therapy, to help patients beyond the standard of care for pain management, rest, and monitoring. A proprietary device and synthetic medication combination developed by Odyssey Health is being tested for safety related to treating concussion patients in the initial moments after a mild injury, successfully completing all three cohorts in the company’s Phase I Single Ascending Dosing (“SAD”) clinical trial recently and advancing to a Multiple Ascending Dosing (“MAD”) stage in which volunteers will be treated once daily for five straight days. “We have a very unique new chemical entity intended to treat mild traumatic brain injury — the acute phase of a concussion,” CEO Michael Redmond said during an interview with The RedChip Money Report(R) last month. “It’s a small device. It essentially goes and delivers a powderized drug through the upper chambers of the nasal cavity. The drug crosses the blood-brain barrier within five minutes. It spreads out throughout the brain within 30 minutes and reverses the effects of a concussion” (https://ibn.fm/sdVcJ). The SAD and MAD clinical trials work with healthy human volunteers to establish the safety of Odyssey Health’s technology, which previously completed preclinical lab animal testing successfully and is expected to advance to a Phase II/III design that will determine the efficacy of the company’s PRV-002 technology for concussed patients. Phase II trial sites are already being identified and the study’s design is being created, working with military board advisers while company officials report their early efforts to the FDA. “We are actively identifying and assisting with Phase II military trial site setup,” Major General (Ret.) Jim Linder, the former chief of staff for the U.S. Special Operations Command, stated in a July 12 news release about Odyssey’s progress (https://ibn.fm/VLE3Q). “We need a treatment to prevent the long-term consequences of concussion as far too many of our Service Members are retiring with TBI disorders that lessen their quality of life.” A significant target of the therapy involves getting the drug across the blood-brain barrier to directly deal with the central nervous system consequences of a head injury. “I am especially excited to see the overall low levels of PRV-002 in the blood supporting the hypothesis that more drug is getting to the brain itself when administered with the intranasal device”, Safety Review Committee member Dallas Hack, MD, stated after analyzing the SAD trial. “If this turns out to be the case, not only can the targeted effects of the drug be more efficacious, the drug will likely have less potential side effects.” For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• MULN shares traded higher after Benzinga stated that the emerging EV manufacturer had reported higher-than-expected battery test results
• Data shows the company’s proprietary solid-state polymer batteries can deliver more than 600 miles of range on a full charge
• The company plans to include the new batteries in its second-generation Mullen FIVE EV Crossover

Mullen Automotive (NASDAQ: MULN) was featured in a recent Benzinga Brief. The short summary noted that the company, an emerging electric-vehicle manufacturer, had reported results of its solid-state polymer battery testing, which exceeded expectations (https://ibn.fm/XI6Fa). Noting that shares were trading higher after the news, Benzinga quoted David Michery, Mullen CEO and chair, as saying, “The battery has performed exceptionally well, and I’m pleased with the results from BIC [Battery Innovation Center] in Indiana.” “Testing results from BIC show the solid-state polymer cell, rated at 300 Ah and 3.7 volts, tested at 343.28 Ah at 4.2 volts, exceeding expectation, and is in line with test tolerance from previous EV Grid test results,” the brief continues. “The data supports solid-state polymer battery cell technology [that], when scaled to the vehicle pack level and at a 150-kilowatt hour equivalent, can deliver over 600 miles of range on a full charge for the Mullen FIVE EV Crossover.” While the company plans to continue to test additional parameters to characterize overall capabilities and performance, these positive results bode well for the Southern California–based company, which owns and partners with synergistic businesses that share the same goal: to create clean, scalable electric vehicles and energy solutions (https://ibn.fm/D8vYz). The company announced plans to include the new solid-state polymer batteries in its second-generation Mullen FIVE EV Crossover (https://ibn.fm/Br0nl). In addition to offering more than 600 miles of range, the batteries can deliver 300 miles of range after an 18-minute DC fast charge. “We’ve conducted successful testing and will begin pack-level development next,” said Michery, who called the future bright for the nascent EV company. Key to the company’s success are several partnerships the company has built recently, including with hofer powertrain, Comau, ARRK, Dürr and DSA Systems. These partners will help Mullen produce improved EV powertrain, engineering, manufacturing, vehicle production systems, and over-the-air (“OTA”) and vehicle system diagnostics. “[Mullen] expects these strategic developments to play a crucial role in bringing the FIVE to market with the latest technology and in the shortest amount of time,” the company stated. The Mullen FIVE RS is a high-performance EV featuring close to 1,100 horsepower, 0 to 60 mph in only 1.95 seconds, and a top speed of almost 200 miles per hour (https://ibn.fm/KaCIj). The vehicle was awarded Top Zero Emission SUV as part of the ZEVA Awards at the Los Angeles International Auto Show in November 2021, where it debuted. For more information about the company, visit www.MullenUSA.com. NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN